Investigational drug · Phase 2
AC01
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure With Reduced Ejection Fraction.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
2
Any phase or sponsor naming "AC01"
First trial start
2023
Feb 23, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AC01", any sponsor or status.
Conditions studied
As listed on its trial records.
- Heart Failure With Reduced Ejection Fraction (HFrEF)
- Heart Failure With Reduced Ejection Fraction
Approved drugs for the same conditions: Heart failure · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "AC01" as an intervention, largest first.
- A Study to Evaluate the Safety and Efficacy of AC01 Compared to Placebo in Participants With Chronic Heart FailurePivotal-lookingRecruiting
AnaCardio ABIndustry
NCT07584967 · 400 participants (planned) · Start Nov 15, 2026 · Primary completion Jul 30, 2028
Drug: AC01 · For: Heart Failure With Reduced Ejection Fraction (HFrEF)
Sites: Van Nuys, California; Crystal River, Florida; Schaumburg, Illinois · 14 sites in all
AnaCardio ABIndustry
NCT05642507 · 58 participants · Start Feb 23, 2023 · Primary completion Oct 27, 2025
Drug: AC01; Placebo Minitablets · For: Heart Failure With Reduced Ejection Fraction
Sites: Brescia, Italy; Trieste, Italy; Amsterdam, Netherlands · 14 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- The Orally Available Ghrelin Receptor-Agonist AC01 Improves Systolic Function in HFrEF Mice and Nonhuman Primates.
Lund LH, Hage C, Carlström M, et al. · JACC Basic Transl Sci 2026
- Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study.
Lund LH, Barandiarán Aizpurua A, Bollano E, et al. · Lancet 2026
- Organizing Pneumonia As the Initial Manifestation of Systemic Lupus Erythematosus: Case Report and Literature Review.
Cespedes Useche LP, Bello JM, Celis Giraldo D, et al. · Cureus 2026
- The ghrelin receptor agonist AC01 improves cardiomyocyte contractility through Gαi signalling and without Ca2+ mobilization.
Lund LH, Hage C, Carlström M, et al. · Cardiovasc Res 2026
- Safety evaluation of the food enzyme cellulase from the non-genetically modified Aspergillus niger strain HBI-AC01.
Zorn H, Barat Baviera JM, Bolognesi C, et al. · EFSA J 2025
- Development of a bacteriophage cocktail with high specificity against high-risk avian pathogenic Escherichia coli.
Norambuena R, Rojas-Martínez V, Tobar-Calfucoy E, et al. · Poult Sci 2025
Also in development for Heart Failure With Reduced Ejection Fraction (HFrEF)
- CRD-4730Phase 22 trials
Cardurion Pharmaceuticals, Inc. · Catecholaminergic Polymorphic Ventricular Tachycardia, Heart Failure With Reduced Ejection Fraction (HFrEF)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.